 |
Ventrus to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 15, 2012
|
9.2 KB |
|
| |
NEW YORK, May 15, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference on Wedne...
|
|
Ventrus Biosciences Announces Positive Results From Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
May 14, 2012
|
69.8 KB |
|
| |
Treatment Arms Show Significant Improvement Over Placebo in Three Major Outcomes
Adverse Events Similar Between Treatment Arms and Placebo
Company to Host Conference Call and Presentation Today, May 14, at 10:00 a.m. ET
NEW YORK, May 14, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported positiv...
|
|
Ventrus Biosciences Reports First Quarter 2012 Financial Results
May 9, 2012
|
14.1 KB |
|
| |
NEW YORK, May 9, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the first quarter ended March 31, 2012.
"Ventrus has achieved several important milestones in recent months, namely the completion of enrollment in pivotal Phase 3 clinical trials for our two lead product candidates, diltia...
|
|
Ventrus to Present at the 37th Annual Deutsche Bank Health Care Conference
May 1, 2012
|
8.6 KB |
|
| |
NEW YORK, May 1, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the 37th Annual Deutsche Bank Health Care Conference on Monday, May 7 a...
|
|
Ventrus Biosciences Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease
Apr 30, 2012
|
11.4 KB |
|
| |
NEW YORK, April 30, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has completed patient enrollment and randomization in the first Phase 3 clinical trial of iferanserin (VEN 309) in patients with grade 1-3 hemorrhoids. Data from the Phase 3 study are anticipated to be available in late June or early July 2012.
...
|
|
Ventrus Announces Two Studies Addressing Hemorrhoid Disease to be Presented at Digestive Disease Week Conference
Mar 8, 2012
|
10.1 KB |
|
| |
NEW YORK, March 8, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that two abstracts submitted to the Digestive Disease Week conference (DDW), to be held in San Diego May 19-22, were accepted for presentation. Both abstracts present data from the omnibus patient survey commissioned by Ventrus of 10,202 consumers an...
|
|
Ventrus to Present at the 24th Annual ROTH OC Growth Stock Conference
Mar 5, 2012
|
8.6 KB |
|
| |
NEW YORK, March 5, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the 24th Annual ROTH OC Growth Stock Conference on Monday, March 12 a...
|
|
Ventrus to Present at Cowen and Company 32nd Annual Health Care Conference
Feb 28, 2012
|
8.6 KB |
|
| |
NEW YORK, Feb. 28, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Cowen and Company 32nd Annual Health Care Conference on Monday, M...
|
|
Ventrus Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease
Jan 13, 2012
|
12.2 KB |
|
| |
NEW YORK, Jan. 13, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), today announced the online publication of the prior Phase 2b study utilizing iferanserin (VEN 309), its novel investigational drug for the treatment of symptomatic hemorrhoids, in the peer reviewed journal Clinical Therapeutics. The article will appear in the Febru...
|
|
Ventrus BioSciences Completes Enrollment of Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
Dec 21, 2011
|
11.9 KB |
|
| |
NEW YORK, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced that S.L.A. Pharma has completed patient enrollment and randomization in the first Phase 3 clinical trial of Diltiazem (VEN 307) in patients with anal fissures. Initial top-line data from the Phase 3 study is expected to be available in May 2012. Ventrus B...
|
|
Ventrus Announces Acquisition of Title to Hemorrhoids Product
Nov 18, 2011
|
9.9 KB |
|
| |
NEW YORK, Nov. 18, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that on November 14, 2011 it completed its acquisition of all rights and title to VEN 309 (iferanserin) from the licensor, Sam Amer & Co.
The total price paid for the asset was US$12.5 million dollars, of which US$0.5 was paid upon execution ...
|
|
Ventrus Reports Third Quarter 2011 Financial Results
Nov 14, 2011
|
10.1 KB |
|
| |
NEW YORK, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) today reported financial results for the third quarter ended September 30, 2011.
In July, Ventrus received net cash proceeds of $47.5 million after closing a secondary public offering. Ventrus ended the third quarter of 2011 with $53.3 million in cash and ca...
|
|
Ventrus Validates Large Patient Potential for VEN 309 With Survey Data From 10,000 Consumers
Nov 14, 2011
|
13.7 KB |
|
| |
NEW YORK, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today an update to the timing for the reporting of the top line results from the ongoing Phase 3 pivotal trial of Iferanserin (VEN 309) in patients with hemorrhoids as well as from the ongoing Phase 3 pivotal trial of Diltiazem (VEN 307) in patients with a...
|
|
Ventrus BioSciences to Announce 3Q 2011 Financial Results, Clinical Update and Omnibus Market Research Results: Conference Call and Webcast
Nov 9, 2011
|
9.2 KB |
|
| |
NEW YORK, Nov. 9, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it will report on its clinical trial progress, the initial topline results of a market research study commissioned by it and conducted by Princeton Biometrics on the U.S. market for hemorrhoids and iferanserin (VEN-309), and third quarter 2011 fi...
|
|
Ventrus Announces the Launch of the First Pivotal Trial of VEN 309 for the Treatment of Hemorrhoids
Aug 16, 2011
|
11.3 KB |
|
| |
NEW YORK, Aug. 16, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that enrollment has opened at 65 of the 70 sites that will participate in the first pivotal Phase III trial of VEN 309 for the treatment of symptomatic hemorrhoids, and patients have now entered the screening process. Ventrus expects that the dosing ...
|
|
Ventrus Biosciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $51.75 Million Underwritten Registered Offering
Jul 19, 2011
|
11.4 KB |
|
| |
NEW YORK, July 19, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced that it closed today its previously announced underwritten registered offering of 5,175,000 shares of common stock at a price to the public of $10.00...
|
|
Ventrus Biosciences Announces Pricing of Its Underwritten Registered Offering of Common Stock
Jul 14, 2011
|
8.9 KB |
|
| |
NEW YORK, July 14, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its underwritten registered offering of 4,500,000 shares of its common stock at a price to the public of $10.00 per share. Ventrus also has ...
|
|
Ventrus Receives SPA Response From FDA and Will Update and File the First Pivotal Trial Protocol to its IND
Jun 22, 2011
|
11.0 KB |
|
| |
NEW YORK, June 22, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) to its last Special Protocol Assessment (SPA) submission for iferanserin (VEN 309) for the treatment of hemorrhoids, and will update the protocol for the company's first...
|
|
Ventrus Receives Notice of Allowance for U.S. Patent for VEN 307
May 31, 2011
|
10.0 KB |
|
| |
NEW YORK, May 31, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. announced today that the claims in its currently pending U.S. Patent Application No. 09/355,928, titled "TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER" were found patentable by the U.S. Patent and Trademark Office and a Notice of Al...
|
|
Ventrus Adds Third Treatment Arm of Shorter Treatment Duration to Its Phase III Study of Iferanserin in Hemorrhoids
May 2, 2011
|
11.4 KB |
|
| |
NEW YORK, May 2, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has added a third treatment arm to its first pivotal Phase III study of Iferanserin (VEN 309), the first prescription product candidate for the treatment of hemorrhoids. The treatment arm has been added based upon a request from the U.S. Food a...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
